HOUSTON, Feb. 9, 2011 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the third quarter ended January 28, 2011 of its fiscal year ending April 29, 2011, on Wednesday, March 2, 2011, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 7:30 AM Central Time (8:30 AM Eastern Time).
Fiscal Year 2011 Third Quarter Results Conference Call InstructionsThe conference call will be available to interested parties through a live audio webcast in the investor relations section of Cyberonics' corporate website at http://www.cyberonics.com, where it will be archived and accessible for approximately 12 months. To listen to the conference call live by telephone dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.). The conference ID is 43242663.
A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). The replay conference ID access code is 43242663. The replay will be available for one week on the above number.
About Cyberonics, Inc. and the VNS Therapy® SystemCyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.Contact InformationGreg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd., Houston, TX 77058Main: (281) 228-7262/Fax: (281) firstname.lastname@example.org
|SOURCE Cyberonics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved